| OMC |
Report |
Organic (core operations) revenue growth |
BEAT |
pred ~4.3% vs. cons ~4.0% |
MEDIUM |
| OMC |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.72 vs. cons ~$2.64 |
MEDIUM |
| OMC |
Report |
Core Adjusted EBITA margin |
BEAT |
pred ~15.2% vs. cons ~14.9% |
MEDIUM |
| OMC |
Guide |
FY2026 constant-currency organic growth guidance |
UNCHANGED |
guide ~4.0% vs. cons ~4.0% (FY2026) |
MEDIUM |
| OMC |
Guide |
FY2026 adjusted EPS growth framing (stepping up from Q1's +11.8%) |
BETTER |
guide ~$11.10 vs. cons ~$10.97 (FY2026) |
MEDIUM |
| OMC |
Guide |
2026 cost synergy capture target |
UNCHANGED |
guide ~$900M vs. cons ~$900M (FY2026) |
HIGH |
| OMC |
Guide |
Year-end 2026 net leverage target |
UNCHANGED |
guide ~2.4x vs. cons ~2.4x (YE2026) |
MEDIUM |
| OMC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| OMC |
Return |
5-day cumulative residual |
+2.5% (FOLLOW-THROUGH) |
A modest EPS/margin beat plus reiterated (not explicitly raised) FY26 organic/EPS guidance should trigger incremental full-year estimate upgrades similar to the post-print reaction seen at Publicis (organic accelerated to 4.8%, guidance raised), supporting gradual re-rating toward the ~$100-103 Street price targets; but because OMC shares already rallied ~12% off June lows into the print, some of the good news is pre-positioned, capping day-1 pop and creating mild give-back risk over days 2-3 before synergy/EPS-trajectory math (higher-double-digit EPS growth needed vs Q1's 11.8%) reasserts a modestly positive drift by day 5 rather than a sharp fade. |
LOW |